About NovelStem
NovelStem is a company based in Boca Raton (United States) founded in 1993 by Mitchell Rubenstein. NovelStem has raised $700 thousand across 2 funding rounds from investors including PJ SOLOMON. NovelStem offers products and services including Diagnostic Technology and Net Force Publishing Franchise. NovelStem operates in a competitive market with competitors including Isabl, CytoSite Bio, Probiont, AccuTheranostics and Precision Therapeutics, among others.
- Headquarter Boca Raton, United States
- Founders Mitchell Rubenstein
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Novelstem International Corp.
-
Annual Revenue
Not available
-
Net Profit
-$3.23 M (USD)23.45as on Dec 31, 2024
-
EBITDA
-$880.95 K (USD)-32.42as on Dec 31, 2024
-
Total Equity Funding
$700 K (USD)
in 2 rounds
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NovelStem
NovelStem offers a comprehensive portfolio of products and services, including Diagnostic Technology and Net Force Publishing Franchise.
Predicts drug resistance for targeted cancer therapies using stem cells.
Manages book series relaunch and licensing agreements.
Funding Insights of NovelStem
NovelStem has successfully raised a total of $700K across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in NovelStem
NovelStem has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include PJ SOLOMON.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
M&A advisory and restructuring services are provided across sectors.
|
Locked | Locked | Locked |
Investor details for NovelStem
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NovelStem
Investment portfolio details for NovelStem
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NovelStem
Detailed financials for NovelStem
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Novelstem Comparisons
Peer comparison for NovelStem
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NovelStem
NovelStem operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Isabl, CytoSite Bio, Probiont, AccuTheranostics and Precision Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cancer patients' genomes are analyzed by a medical diagnosis platform.
|
|
| Locked | Locked | Locked |
Precision imaging products for immuno-oncology therapy are developed.
|
|
| Locked | Locked | Locked |
Developing personalized solutions for cancer immunotherapy testing with organ-on-a-chip technology.
|
|
| Locked | Locked | Locked |
Personalized chemotherapy response testing is offered for cancer patients.
|
|
| Locked | Locked | Locked |
Precision Therapeutics develops a platform for innovative, personalized cancer therapies.
|
Detailed competitors of NovelStem
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Novelstem
Complete news archive for NovelStem
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NovelStem
NovelStem was founded in 1993 and raised its 1st funding round 17 years after it was founded.
NovelStem is headquartered in Boca Raton, United States. It is registered at Boca Raton, Florida, United States.
Mitchell Rubenstein is the current CEO of NovelStem. They have also founded this company.
NovelStem is a funded company, having raised a total of $700K across 2 funding rounds to date.
NovelStem was founded in 1993 and is headquartered in Boca Raton, United States. Operations focus on biotechnology, where proprietary haploid human embryonic stem cell technology, known as NewStem, is utilized to create diagnostics that predict patient resistance to cancer chemotherapies. Additional efforts include development of therapeutics and applications in reproductive medicine.
NovelStem's top competitors include CytoSite Bio, Isabl and Probiont.
NovelStem offers Diagnostic Technology and Net Force Publishing Franchise.
NovelStem has 1 investor. Key investors include PJ SOLOMON.